The life sciences business developing compounds to tackle obesity, high cholesterol and diabetes today released its annual report for the year ending November 2014. The results themselves are not reflective of the value being built within the company, covering only four months of trading in the underlying business, which is still in the development phase. However net losses totaled £0.8m of which £365k related to admission expenses. Following the £3.3m placing the year end c
29 May 2015
More IP, scientific advances and a growing focus on commercialisation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
More IP, scientific advances and a growing focus on commercialisation
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
29 May 2015 -
Author:
Derren Nathan -
Pages:
6
The life sciences business developing compounds to tackle obesity, high cholesterol and diabetes today released its annual report for the year ending November 2014. The results themselves are not reflective of the value being built within the company, covering only four months of trading in the underlying business, which is still in the development phase. However net losses totaled £0.8m of which £365k related to admission expenses. Following the £3.3m placing the year end c